Search
01/01/2023
Corrigendum: The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases(Front. Immunol., (2023), 14, (1191782), 10.3389/fimmu.2023.1191782)
Navarro-Compán V., Puig L., Vidal S., Ramírez J., Llamas-Velasco M., Fernández-Carballido C., Almodóvar R., Pinto J.A., Galíndez-Aguirregoikoa E., Zarco P., Joven B., Gratacós J., Juanola X., Blanco R., Arias-Santiago S., Sanz J.S., Queiro R., Cañete J.D.. Corrigendum: The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases(Front. Immunol., (2023), 14, (1191782), 10.3389/fimmu.2023.1191782). Frontiers in Immunology. 2023; 14DOI:10.3389/fimmu.2023.1332177. PMID:. IF:(Q/D).
30/12/2022
The Benefits of Early versus Late Therapeutic Intervention in Fabry Disease.
Furlano M, Ars E, Matamala A, Brossa V, Martí J, Del Prado-Venegas M, Crespi J, Roe E, Torra R. The Benefits of Early versus Late Therapeutic Intervention in Fabry Disease.. Case Reports In Genetics. 2022; 2022DOI:10.1155/2022/3208810. PMID:36619006. IF:(Q/D).
01/06/2025
Baseline Characteristics and Treatment Patterns of Patients with Atopic Dermatitis Treated with Oral Systemic Therapies: An Interim Analysis of the AD-REAL Study
Augustin, M, Serra-Baldrich, E, Seneschal, J, Grond, S, Lampropoulou, A, Elrayes, M, Ogwu, S, de la Torre, I, Bewley, A, Pinter, A. Baseline Characteristics and Treatment Patterns of Patients with Atopic Dermatitis Treated with Oral Systemic Therapies: An Interim Analysis of the AD-REAL Study. ADVANCES IN THERAPY. 2025; 42(6)DOI:10.1007/s12325-025-03137-3. PMID:40192965. IF:4.000(Q1/3D).
01/06/2025
Cholinergic Pruritus as an Early Sign of Essential Thrombocythemia With Therapeutic Response to Ruxolitinib
Mateu-Arrom, L, Serra-Baldrich, E, Puig, L. Cholinergic Pruritus as an Early Sign of Essential Thrombocythemia With Therapeutic Response to Ruxolitinib. Actas Dermo-Sifiliograficas. 2025; 116(6)DOI:10.1016/j.ad.2023.09.035. PMID:39947585. IF:(Q/D).
01/05/2025
Oral mucosal papules in an immunosuppressed girl
Peirano, F, Rusiñol, L, Iznardo, H, Carmona-Rocha, E, Puig, L, Roé, E. Oral mucosal papules in an immunosuppressed girl. CLINICAL AND EXPERIMENTAL DERMATOLOGY. 2025; 50(5)DOI:10.1093/ced/llaf007. PMID:39775820. IF:2.800(Q2/4D).
01/05/2025
Multicenter, Prospective, Case-Control Study of Exposome in Melanoma
Navarro-Bielsa, A, Gracia-Cazaña, T, Almagro, M, De-la-Fuente-Meira, S, Florez, A, Yélamos, O, Montero-Vilchez, T, González-Cruz, C, Diago, A, Abadías-Granado, I, Fuentelsaz, V, Colmenero, M, Bañuls, J, Arias-Santiago, S, Buendía-Eisman, A, Almenara-Blasco, M, Gil-Pallares, P, Gilaberte, Y. Multicenter, Prospective, Case-Control Study of Exposome in Melanoma. Actas Dermo-Sifiliograficas. 2025; 116(5)DOI:10.1016/j.ad.2024.09.022. PMID:39756676. IF:(Q/D).
01/04/2025
Histological deep margins in cutaneous squamous cell carcinoma of the scalp and risk of recurrence
Verdaguer-Faja, J, Guerra-Amor, A, Ferrándiz-Pulido, C, Abril-Pérez, C, Estrada, RB, Masferrer, E, Lopez-Castillo, D, Deza, G, Leal, L, Marti-Marti, I, Ruiz-Salas, V, Yébenes, M, Martin, LM, Baliu, C, Castany, A, Boada, A, Toll, A, Jaka, A. Histological deep margins in cutaneous squamous cell carcinoma of the scalp and risk of recurrence. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2025; 39(4)DOI:10.1111/jdv.20250. PMID:39036869. IF:8.000(Q1/1D).
01/04/2025
Parental Assessment of Infantile Hemangioma Cosmetic Clinical Outcomes: Results of the Spanish Hemangioma Nationwide Prospective Cohort
Colmenero-Sendra, M, del Boz-González, J, Torres, EB, Bernabéu-Wittel, J, Roé-Crespo, E, Vicente, A, Valdivieso-Ramos, M, Martín-Santiago, A, Palencia-Pérez, SI, Montserrat-García, MT, Azón-Masoliver, A, Dañino, M, Prims, CT, Prat, C, Giacaman, A, Domínguez-Cruz, JJ, Alonso, AB, Grau-Pérez, M, Descalzo, MA, García-Doval, I. Parental Assessment of Infantile Hemangioma Cosmetic Clinical Outcomes: Results of the Spanish Hemangioma Nationwide Prospective Cohort. Actas Dermo-Sifiliograficas. 2025; 116(4)DOI:10.1016/j.ad.2024.06.010. PMID:39032773. IF:(Q/D).